MedTrace Logo

A Study to Evaluate RIST4721 in Familial Mediterranean Fever (FMF)

NCT05448391 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-02-13

No results posted yet for this study

Summary

A 12-week Open-label, Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of RIST4721 in Subjects with Familial Mediterranean Fever followed by an additional Open-label Extension Phase.

Conditions

  • Familial Mediterranean Fever

Interventions

DRUG

RIST4721

RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets

Sponsors & Collaborators

  • Aristea Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-13
Primary Completion
2023-11-30
Completion
2024-12-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05448391 on ClinicalTrials.gov